Quantitative assessment of cibenzoline administration for vagally mediated paroxysmal atrial fibrillation using frequency-domain heart rate variability analysis

Journal of Cardiology

Volumn 54, Issue 1, 2009, Pages 86-92

  Miyakoshi, Mutsumi ^a   Ikeda, Takanori ^a   Miwa, Yosuke ^a   Sakaki, Katsura ^a   Ishiguro, Haruhisa ^a   Abe, Atsuko ^a   Tsukada, Takehiro ^a   Mera, Hisaaki ^a   Yusu, Satoru ^a   Yoshino, Hideaki ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiarrhythmic drug; Anticholinergic action; Cibenzoline; Muscarinic receptor; Paroxysmal atrial fibrillation; Vagal type

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIBENZOLINE; DISOPYRAMIDE; VERAPAMIL; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; MALE; QUANTITATIVE ANALYSIS; VAGUS TONE;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHOLINERGIC ANTAGONISTS; DISOPYRAMIDE; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART RATE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 67650998693     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2009.04.009     Document Type: Article

References (19)

1. Fuster V., Rydén L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Le Heuzey J.Y., Kay G.N., Lowe J.E., Olsson S.B., Prystowsky E.N., Tamargo J.L., Wann S., Smith Jr. S.C., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Circulation 114 (2006) e257-e354
2. Japanese Circulation Society. JCS 2004 guidelines for pharmacotherapy of atrial fibrillation: a report of the Japanese Circulation Society committee for diagnosis and treatment of cardiovascular diseases. Circ J 72 Suppl. IV (2008) 1581-1638 [in Japanese]
3. Malik M. Heart rate variability and baroreflex sensitivity. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology: from cell to bedside (2004), Saunders, Philadelphia 823-830
4. Akselrod S., Gordon D., Ubel F.A., Shannon D.C., Berger A.C., and Cohen R.J. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 213 (1981) 220-222
5. Herweg B., Dalal P., Nagy B., and Schweitzer P. Power spectral analysis of heart period variability of preceding sinus rhythm before initiation of paroxysmal atrial fibrillation. Am J Cardiol 82 (1998) 869-874
6. Tomita T., Takei M., Saikawa Y., Hanaoka T., Uchikawa S., Tsutsui H., Aruga M., Miyashita T., Yazaki Y., Imamura H., Kinoshita O., Owa M., and Kubo K. Role of autonomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients without structural heart disease. J Cardiovasc Electrophysiol 14 (2003) 559-564
7. 1 blocker in patients with paroxysmal atrial fibrillation. Int Heart J 49 (2008) 281-293
8. Korpelainen J.T., Sotaniemi K.A., Huikuri H.V., and Myllylä V.V. Circadian rhythm of heart rate variability is reversibly abolished in ischemic stroke. Stroke 28 (1997) 2150-2154
9. Sugiura H., Chinushi M., Komura S., Hirono T., and Aizawa Y. Heart rate variability is a useful parameter for evaluation of anticholinergic effect associated with inducibility of atrial fibrillation. Pacing Clin Electrophysiol 28 (2005) 1208-1214
10. Komatsu T., Tachibana H., Sato Y., Ozawa M., Ohshima K., Orii M., Kunigida F., and Nakamura M. A randomized study on the efficacy of intravenous cibenzoline and pilsicainide administered prior to electrical cardioversion in patients with lone paroxysmal and persistent atrial fibrillation. J Cardiol 53 (2009) 35-42
11. Yamashita T., Murakawa Y., Hayami N., Sezaki K., Inoue M., Fukui E., and Omata M. Relation between aging and circadian variation of paroxysmal atrial fibrillation. Am J Cardiol 82 (1998) 1364-1367
12. Pappano A. Parasympathetic control of cardiac electrical activity. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology: from cell to bedside (1990), Saunders, Philadelphia 271-277
13. Coumel P. Neural aspects of paroxysmal atrial fibrillation. In: Falk R.H., and Podrid P.J. (Eds). Atrial fibrillation: mechanisms and management (1992), Raven Press, New York 109-125
14. Schuessler R.B., Grayson T.M., Bomberg B.I., Cox J.L., and Boineau J.P. Cholinergically mediated tachyarrhythmias induced by a single extrastimulus in the isolated canine right atrium. Circ Res 71 (1992) 1254-1267
15. Ikeda T., Wu T.-J., Uchida T., Hough D., Fishbein M.C., Mandel W.J., Chen P.S., and Karagueuzian H.S. Meandering and unstable reentrant wave fronts induced by acetylcholine in isolated canine right atrium. Am J Physiol 273 (1997) H356-H370
16. Schauerte P., Scherlag B.J., Pitha J., Scherlag M.A., Reynolds D., Lazzara R., and Jackman W.M. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation 102 (2000) 2774-2780
17. Wu S.N., Nakajima T., Yamashita T., Hamada E., Hazama H., Iwasawa K., Omata M., and Kurachi Y. Molecular mechanism of cibenzoline-induced anticholinergic action in single atrial myocytes: comparison with effect of disopyramide. J Cardiovasc Pharmacol 23 (1994) 618-623
18. Yamamoto N., Ozaki T., Keida Y., Ohtsuka M., and Goto T. A comparison of the binding characteristics of class I antiarrhythmic agents for human muscarinic m1-m3 receptors. J Cardiovasc Pharmacol 34 (1999) 53-59
19. Atarashi H., Ogawa S., and Inoue H. Relationship between subjective symptoms and trans-telephonic ECG findings in patients with symptomatic paroxysmal atrial fibrillation and flutter. J Cardiol 52 (2008) 102-110